Skip to main content
. Author manuscript; available in PMC: 2013 Dec 2.
Published in final edited form as: Cancer Prev Res (Phila). 2010 Feb 23;3(3):10.1158/1940-6207.CAPR-09-0188. doi: 10.1158/1940-6207.CAPR-09-0188

Table 2.

Distributions of C-Peptide in the Prostate Cancer Prevention Trial

Baseline Serum C-peptide (ng/ml)
n Mean SD 25th%
tile 		50th
%tile 		75
%tile
All
participants		 3600 3.64 2.32 1.86 3.08 4.88
Cases 1803 3.64 2.32 1.87 3.14 4.87
Controls 1797 3.63 2.33 1.84 3.03 4.90
Baseline and Year 2 Serum C-Peptide (ng/ml) 1
n Baseline
Median 		Baseline
Mean 		SD Year 2
Median 		Year 2
Mean 		SD
All
Participants1 		267 3.08 3.56 2.18 4.06 4.46 2.71
Cases
 All cases 127 3.32 3.84 2.25 4.32 4.78 2.77
 Placebo 67 3.21 3.60 2.05 4.27 4.46 2.64
 Finasteride 60 3.91 4.10 2.45 4.52 5.13 2.89
Controls
 All controls 140 2.78 3.32 2.08 3.58 4.14 2.62
 Placebo 73 2.76 3.23 2.05 3.81 4.24 2.46
 Finasteride 67 2.89 3.41 2.13 3.11 4.03 2.80
1

Subset of randomly selected participants (n=267) had repeat measures.